Format

Send to

Choose Destination
Inflamm Bowel Dis. 2019 Apr 13. pii: izz068. doi: 10.1093/ibd/izz068. [Epub ahead of print]

Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.

Author information

1
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.

Abstract

Inflammatory bowel diseases are known for a chronic inflammatory process of the gastrointestinal tract and include Crohn's disease and ulcerative colitis (UC). Patients who are dependent on or resistant to corticosteroids account for about 20% of severe UC patients. Tacrolimus is a calcineurin inhibitor that has recently been used in the treatment of steroid-refractory ulcerative colitis. Tacrolimus has been demonstrated to have remarkable therapeutic efficacy in UC patients, without increased risk of severe adverse effects such as induction of remission and maintenance therapy. This article reviews the mechanism of action, pharmacogenetics, efficacy, and safety of tacrolimus for patients with steroid-refractory ulcerative colitis.

KEYWORDS:

CYP3A5 genotype; calcineurin inhibitor; induction of remission; steroid-refractory ulcerative colitis; tacrolimus

PMID:
30980713
DOI:
10.1093/ibd/izz068

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center